Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.Blood|February 24, 2007
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Ute Berger, Markus Pfirrmann, et al.Clinical Lymphoma, Myeloma & Leukemia|March 8, 2018
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI SubtrialSébastien Rinaldetti, Markus Pfirrmann, Kirsi Manz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Journal of Neurology|March 22, 2022
Decline in the number of patients with meningitis in German hospitals during the COVID-19 pandemicStefanie Völk, Markus Pfirrmann, Uwe Koedel, et al.Pageof 6